Shield Therapeutics Share Price (STX)

33.00 -0.50 (-1.49%) delayed: 6:05PM BST
Bid price 32.00 Open price 33.00
Ask price 34.00 Prev close 33.00
High price 33.00 Spread 5.88%
Low price 31.00 Volume 59,271

Register now for FREE live Shield Therapeutics share prices, Shield Therapeutics stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Shield Therapeutics Level 2 Data, indepth research tools and investor commentary for Shield Therapeutics (STX) and other London Stock Exchange equities.

Shield Therapeutics Share Price Chart

Advanced Charts >>

Register now for FREE Shield Therapeutics share price charts

Shield Therapeutics Share Price Information

Name Shield Therapeutics Epic STX
Sector Pharmaceuticals & Biotechnology ISIN GB00BYV81293
Activites Shield Therapeutics plc is a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs. Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru, for the treatment of IDA in adult patients with IBD which has exclusive IP rights until the mid-2030's. Index n/a

Shield Therapeutics Key Numbers

Latest Share Price (p) 33.00 Net Gearing (%) -21.21
Market Capitalisation (£m) 39.00 Gross Gearing (%) 8.37
Shares in issue (m) 116.43 Debt Ratio 0.00
P/E Ratio -1.97 Debt-to-Equity Ratio 0.00
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.09
Dividend Yield (%) 0.00 Price to book value 0.95
Dividend cover (x) 0.00 ROCE (%) -50.93
Earning per share (p) -17.00 EPS Growth (%) -13.33
52 week high / low 160.00 / 15.10 DPS Growth (%) n/a

Shield Therapeutics Director Deals

Dec.Date Type Director Pos No. of Shares
24/09/2018 BUY Carl Sterritt CEO 88,235
05/10/2017 BUY Carl Sterritt CEO 8,814

More Shield Therapeutics Director Deals >>

Shield Therapeutics Company News

13:54 01/10/2018

Notification Of Major Holdings

RNS Number : 5604C Shield Therapeutics PLC 01 October 2018   TR-1: S tandard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i...

07:17 01/10/2018

Shield Therapeutics gets FDA confirmation for drug application

Shield Therapeutics said it received confirmation from the US Federal Drug Administration of a successful submission of a new drug application for iron deficiency treatment Feraccru. The product was already approved in the European Union for the treatment of iron deficiency in adults and in...

07:00 01/10/2018

Submission of an NDA for Feraccru

RNS Number : 4323C Shield Therapeutics PLC 01 October 2018   Shield Therapeutics plc ("Shield" or the "Group") Shield Therapeutics announces submission of a New Drug Application (NDA) for Feraccru ®   for the treatment of iron deficiency with the US Food and Drug...

More Shield Therapeutics Company News >>

Register now for FREE Shield Therapeutics company news

Shield Therapeutics Share Price Discussions

more than 1 year ago

Seagate Technology (STX)

traded on Nasdaq - anyone holding? PE of 4 and company on a buy back mission

Register now for FREE Shield Therapeutics share price discussions